Expression, Purification and Characterization of GMZ2’.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite

Pharmaceutical Research

Volumn 34, Issue 9, 2017, Pages 1970-1983

  Mistarz, Ulrik H ^a   Singh, Susheel K ^a,b,c   Nguyen, Tam T T N ^a   Roeffen, Will ^d   Yang, Fen ^a   Lissau, Casper ^a   Madsen, Søren M ^e   Vrang, Astrid ^e   Tiendrebeogo, Régis W ^a,b,c   Kana, Ikhlaq H ^a,b,c   Sauerwein, Robert W ^d   Theisen, Michael ^a,b,c   Rand, Kasper D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c University of Copenhagen   (Denmark)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BIONEER A S   (Denmark)

Author keywords

disulphide bond mapping; malaria vaccine; mass spectrometry of biopharmaceuticals; Pfs48 45; production and stability analysis of biopharmaceuticals

Indexed keywords

DISULPHIDE BONDED FUSION PROTEIN VACCINE; HYBRID PROTEIN; MALARIA VACCINE; UNCLASSIFIED DRUG; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; IMMUNOAFFINITY CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALARIA FALCIPARUM; MOLECULAR WEIGHT; NONHUMAN; PEPTIDE MAPPING; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIZE EXCLUSION CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; VACCINATION; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; CHEMISTRY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LACTOCOCCUS LACTIS; MOLECULAR CLONING; PARASITOLOGY; PROTEIN STABILITY; WISTAR RAT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CLONING, MOLECULAR; HUMANS; LACTOCOCCUS LACTIS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTEIN STABILITY; PROTOZOAN PROTEINS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS;

EID: 85021188094     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-017-2208-1     Document Type: Article

References (40)

1. WHO. World Malaria Report 2015. Geneva, Switzerland: World Health Organization, 2015 December. Report No.: 8.
2. Bhatt S, Weiss D, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207–11.
3. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8(1):e1000406.
4. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis. 2000;181(3):1202–5.
5. Meraldi V, Nebie I, Tiono AB, Diallo D, Sanogo E, Theisen M, et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol. 2004;26(6–7):265–72.
6. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 1994;84:1594–602.
7. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun. 2004;72(1):247–52.
8. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE, Esen M, Theisen M, Mordmuller B, Wardemann H. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med. 2013.
9. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun. 1998;66(1):11–7.
10. Sirima SB, Mordmüller B, Milligan P, Ngoa UA, Kironde F, Atuguba F, et al. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine. 2016;34(38):4536–42.
11. Vermeulen AN, Ponnudurai T, Beckers P, Verhave J, Smits M, Meuwissen J. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med. 1985;162(5):1460–76.
12. Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, et al. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. Vaccine. 2015;33(16):1981–6.
13. Roeffen W, Theisen M, Vegte-Bolmer M, Gemert G, Arens T, Andersen G, et al. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants. Malaria J. 2015;14(1):1.
14. Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vegte-Bolmer M, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine. 2014;32(22):2623–30.
15. Gerloff DL, Creasey A, Maslau S, Carter R. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum. Proc Natl Acad Sci U S A. 2005;102(38):13598–603.
16. Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, et al. Epitope analysis of the malaria surface antigen Pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. J Biol Chem. 2007;282(23):17148–56.
17. Arredondo SA, Cai M, Takayama Y, MacDonald NJ, Anderson DE, Aravind L, et al. Structure of the Plasmodium 6-cysteine s48/45 domain. Proc Natl Acad Sci U S A. 2012;109(17):6692–7.
18. Carter R, Graves PM, Keister DB, Quakyi IA. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immununol. 1990;12(6):587–603.
19. Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A. 2008;105(11):4301–5.
20. Kocken CH, Jansen J, Kaan AM, Beckers PJ, Ponnudurai T, Kaslow DC, et al. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol Biochem Parasit. 1993;61(1):59–68.
21. Jones CS, Luong T, Hannon M, Tran M, Gregory JA, Shen Z, et al. Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii. Appl Microbiol Biotechnol. 2013;97(5):1987–95.
22. Baldwin SL, Roeffen W, Singh SK, Tiendrebeogo RW, Christiansen M, Beebe E, et al. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen. Vaccine. 2016;34(19):2207–15.
23. Jørgensen CM, Vrang A, Madsen SM. Recombinant protein expression in Lactococcus lactis using the P170 expression system. FEMS Microbiol Lett. 2014;351(2):170–8.
24. Holo H, Nes IF. Transformation of Lactococcus by Electroporation. In: Nickoloff JA, editor. Electroporation protocols for microorganisms. Methods Mol Biol. 1995;47:195–9.
25. Ejima D, Yumioka R, Arakawa T, Tsumoto K. Arginine as an effective additive in gel permeation chromatography. J Chromatogr A. 2005;1094(1):49–55.
26. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis. 2000;181(3):1202–5.
27. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947:50–60.
28. Liebman HA, Limentani SA, Furie BC, Furie B. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex. Proc Natl Acad Sci U S A. 1985;82(11):3879–83.
29. Thim L, Vandahl B, Karlsson J, Klausen N, Pedersen J, Krogh T, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349–59.
30. Agraz A, Duarte CA, Costa L, Pérez L, Páez R, Pujol V, et al. Immunoaffinity purification of recombinant hepatitis B surface antigen from yeast using a monoclonal antibody. J Chromatogr A. 1994;672(1):25–33.
31. Leurs U, Mistarz UH, Rand KD. Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry. Eur J Pharm Biopharm. 2015;93:95–109.
32. Leurs U, Mistarz UH, Rand KD. Applications of mass spectrometry in drug development science. In: Müllertz A, Perrie Y, Rades T, editors. Analytical techniques in the pharmaceutical sciences. Advances in delivery science and technology. New York: Springer; 2016.
33. Donnarumma D, Faleri A, Costantino P, Rappuoli R, Norais N. The role of structural proteomics in vaccine development: recent advances and future prospects. Expert Rev Proteomics. 2016;13(1):55–68.
34. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501–7.
35. Frøkjær S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298–306.
36. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;20(9):1325–36.
37. Hong P, Koza S, Bouvier ES. A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol. 2012;35(20):2923–50.
38. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, et al. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res. 2011;28(4):920–33.
39. Hemmings H, Nairn A, Aswad D, Greengard P. DARPP-32, a dopamine-and adenosine 3′: 5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus. J Neurosci. 1984;4(1):99–110.
40. Betz SF. Disulfide bonds and the stability of globular proteins. Protein Sci. 1993;2(10):1551–8.